FERIDEX I.V.
LOE Approachingferumoxides
NDAINJECTIONINJECTABLE
Approved
Aug 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FERIDEX I.V. (ferumoxides) is clinical pharmacology general: feridex i. First approved in 1996.
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERIDEX I.V. (ferumoxides) is a superparamagnetic iron oxide contrast agent administered intravenously for magnetic resonance imaging (MRI). It is taken up by cells of the reticuloendothelial system (RES) and shortens relaxation times for hydrogen atoms, creating signal loss in normal tissues while preserving signal in abnormal tissues with reduced RES function. This mechanism enhances contrast between healthy and diseased liver tissue.
LOE Approaching
Product approaching loss of exclusivity with minimal current career opportunity signal; legacy imaging agent facing market consolidation and limited hiring.
Mechanism of Action
CLINICAL PHARMACOLOGY General: Feridex I.V. is an intravenously injected colloidal superparamagnetic iron oxide associated with dextran. It is a magnetic resonance imaging (MRI) contrast agent and is taken up by cells of the reticuloendothelial system (RES). Pharmacokinetics: Three healthy, adult…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.